Latest Insider Transactions at Cidara Therapeutics, Inc. (CDTX)
This section provides a real-time view of insider transactions for Cidara Therapeutics, Inc. (CDTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cidara Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cidara Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2021
|
Brady Johnson Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
262
+0.51%
|
-
|
|
Dec 29
2021
|
Jeffrey Stein President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.92%
|
-
|
|
Dec 29
2021
|
Paul Daruwala Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,900
+4.89%
|
-
|
|
Nov 12
2021
|
Preetam Shah Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$20,000
$1.54 P/Share
|
|
Nov 12
2021
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+9.69%
|
$50,000
$1.59 P/Share
|
|
Sep 30
2021
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
148,000
+49.57%
|
-
|
|
Sep 30
2021
|
Paul Daruwala Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
132,000
+41.97%
|
-
|
|
Sep 30
2021
|
Taylor Sandison Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,600
+38.89%
|
-
|
|
Sep 30
2021
|
Brady Johnson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
20,750
+30.54%
|
-
|
|
Sep 13
2021
|
Timothy R Franson Director |
BUY
Open market or private purchase
|
Direct |
7,000
+38.89%
|
$14,000
$2.12 P/Share
|
|
Aug 19
2021
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+2.35%
|
$10,000
$1.79 P/Share
|
|
Aug 18
2021
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Direct |
40,000
+8.97%
|
$40,000
$1.72 P/Share
|
|
Apr 01
2021
|
Jessica Oien General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
1,177
-13.16%
|
$2,354
$2.66 P/Share
|
|
Apr 01
2021
|
Paul Daruwala Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
593
-1.16%
|
$1,186
$2.66 P/Share
|
|
Apr 01
2021
|
Neil Abdollahian Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,469
-2.49%
|
$2,938
$2.66 P/Share
|
|
Mar 31
2021
|
Jeffrey Stein President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+2.69%
|
-
|
|
Mar 31
2021
|
Taylor Sandison Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
700
+0.85%
|
-
|
|
Mar 31
2021
|
Jessica Oien General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,800
+23.85%
|
-
|
|
Mar 31
2021
|
Paul Daruwala Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,400
+2.67%
|
-
|
|
Mar 31
2021
|
Neil Abdollahian Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,500
+5.61%
|
-
|
|
Jan 05
2021
|
Jessica Oien General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
824
-11.83%
|
$1,648
$2.06 P/Share
|
|
Jan 05
2021
|
Paul Daruwala Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,868
-5.45%
|
$5,736
$2.06 P/Share
|
|
Jan 05
2021
|
Neil Abdollahian Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,868
-4.92%
|
$5,736
$2.06 P/Share
|
|
Nov 10
2020
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$100,000
$2.01 P/Share
|
|
Nov 10
2020
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+12.57%
|
$100,000
$2.0 P/Share
|